33 assets in Acute Myeloid Leukemia With Multilineage Dysplasia

Therapeutic assets addressing Acute Myeloid Leukemia With Multilineage Dysplasia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cytarabine Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P3	BB (70)
Etoposide Acute Myeloid Leukemia With Multilineage Dysplasia	Institut de Recherches Internationales Servier	P2	BB (68)
Decitabine Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P3	BB (67)
Cyclophosphamide Acute Myeloid Leukemia With Multilineage Dysplasia	City of Hope Medical Center	P3	BB (66)
Fludarabine Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P3	BB (66)
Ivosidenib Acute Myeloid Leukemia With Multilineage Dysplasia	Institut de Recherches Internationales Servier	P3	BB (66)
Busulfanum Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P3	BB (64)
Azacitidine Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P3	B (62)
Mitoxantrone Acute Myeloid Leukemia With Multilineage Dysplasia	Institut de Recherches Internationales Servier	P2	B (62)
Clofarabine Acute Myeloid Leukemia With Multilineage Dysplasia	M.D. Anderson Cancer Center	P3	B (61)
Daunomycin Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P2	B (60)
Enasidenib Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P2	B (60)
Idarubicin Acute Myeloid Leukemia With Multilineage Dysplasia	University of Southern California	P1/2	B (57)
Melphalan Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P2	B (57)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Acute Myeloid Leukemia With Multilineage Dysplasia	M.D. Anderson Cancer Center	P2	B (56)
Cedazuridine Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P2	CCC (53)
Cpx-351 Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P2	CCC (53)
Emavusertib Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P2	CCC (53)
Epoetin Alfa Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P2	CCC (53)
Gemtuzumab Ozogamicin Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P2	CCC (53)
Gilteritinib Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P2	CCC (53)
Glasdegib Acute Myeloid Leukemia With Multilineage Dysplasia	University of California, Irvine	P2	CCC (53)
Luspatercept Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P2	CCC (53)
NK-92 Acute Myeloid Leukemia With Multilineage Dysplasia	M.D. Anderson Cancer Center	P2	CCC (53)
Olutasidenib Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P2	CCC (53)
Pomalidomide Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P2	CCC (53)
Rituximab Acute Myeloid Leukemia With Multilineage Dysplasia	M.D. Anderson Cancer Center	P2	CCC (53)
Venetoclax Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P2	CCC (53)
Atezolizumab Acute Myeloid Leukemia With Multilineage Dysplasia	University of Southern California	P1/2	CCC (48)
Guadecitabine Acute Myeloid Leukemia With Multilineage Dysplasia	University of Southern California	P1/2	CCC (48)
Pevonedistat Acute Myeloid Leukemia With Multilineage Dysplasia	University of Southern California	P1/2	CCC (48)
Ipilimumab Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P1	CC (43)